anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a fashionable tea therapy method capable of treating mammary gland hyperplasia according to the traditional Chinese medical science. According to the traditional Chinese medical science, mammary gland hyperplasia belongs to the fields of acute mastitis and breast pain, is a woman's frequently-occurring disease, and is common in middle-aged women. Mammary gland hyperplasia is a dyshormonism-caused hyperplastic disease, and is caused by mammary gland parenchyma hyperplasia and subinvolution produced by female estrogen-progestin ratio imbalance. Mammary gland hyperplasia has symptoms that before the menstruation, breast distending pain is aggravated and breast lumps are produced; and after the menstruation, the breast distending pain and the breast lumps are relieved or disappear. The fashionable tea therapy method is a Chinese herbal medicine therapy method and is simple and easy for operation. A result of a clinical practice shows that the fashionable tea therapy method has obvious treatment effects through continuous utilization lasting for a month, wherein utilization is avoided in the menstruation.
Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
This group includes 15 healthy overweight volunteers. These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.
The present invention provides a method of stimulating dendritic cells, comprising contacting the dendritic cells with methionine enkephalin. The present invention also provides methods of enhancing an immune response to an antigen in a mammal. In a first method, dendritic cells are isolated from the mammal. The dendritic cells are then contacted with methionine enkephalin for a time sufficient to stimulate the cells. Next, the stimulated dendritic cells are contacted with the antigen of interest for a time sufficient for the cells to process the antigen. The dendritic cells are then injected into the mammal. The dendritic cells may be injected into the animal either on their own, or along with methionine enkephalin and/or the antigen. In a second method, the antigen of interest and methionine enkephalin are administered to the mammal. The present invention also provides compositions for administration to a mammalian subject having a tumor.
An on-line system is disclosed for enabling and maintaining a plurality of separate user specific versions of a user configurable electronic textbook. The textbook includes a template stored in a master database table and an associated user specific database table for storing personalized subject matter. The template may include certain images and textual content as well as subject matter organizational outline. The system allows a user to upload images to the system under a specific heading of the organizational outline in the template. The images can be annotated and stored in a user specific database. The user specific database is not accessible to other users of the on-line system. Thus, users may create a personalized electronic textbook. In one embodiment of the invention, the administrator can upload images from the various users to the master database table so that those images can be made available to other users.
NEW MATERIAL:A dipeptide compound expressed by formulaI(R<1> and R<2> are alkyl which may be substituted by indolyl group; Y is aryl, al-lower alkenyl which may have a substituent group; Z is H or salt-forming cation). EXAMPLE:N-[N-(3,4,5-Trihydroxybenzoyl)-(L)-leucyl]-(L)-leucine. USE:An antiulcer agent having improved inhibitory action on the secretion and a high safety without side effects due to the anticholinergic action. PROCESS:A compound expressed by formula II is reacted with a reactive derivative of a carboxylic acid expressed by formula III, and if desired the salt forming reaction is carried out to give the compound expressed by formulaI. The reaction is carried out in a solvent, e.g.THF, in the presence or absence of a deacidifying agent at room temperature -100 deg.C for 10min-5hr. The compound expressed by formula III is used in an amount equimolar with, preferably 1.05-1.2times, the molar amount of the compound expressed by formula II.
The invention involves methods and materials for extracellularly administering PNA oligomers to living cells. Specifically, the invention provides methods and materials of treating living cells with PNA oligomers such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. In addition, the invention provides methods and materials for orally administering PNA oligomers to animals such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. The invention also provides sense and antisense PNA oligomers that modulate transcription and translation, respectively. The invention also provides mismatch PNA oligomers that modulate the degree of an engendered biological response. In addition, the invention provides methods and materials for detecting PNA oligomers within a biological sample collected from an animal. Further, the invention provides methods and materials for screening potential PNA oligomers for the ability to engender a sequence specific biological response. Further, the invention provides methods of identifying the function of polypeptides and of determining the relative turnover rate of functional polypeptides.
Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
OBJECTIVE: F-18-fluorothymidine (FLT) is a positron emission tomography (PET) tracer for imaging cell proliferation in vivo. We aimed to assess FLT uptake as a marker for cerebral cell proliferation in a rat model of ischemic stroke and patients with cerebral infarct, correlating with disease severity and outcomes.
METHODS: Cerebral FLT PET was performed in rats subjected to transient middle cerebral artery occlusion (MCAO) and patients with cerebral infarct. PET data were analyzed and expressed as average standardized uptake value ratios (SUVRs) using cerebellar cortex as reference. Infarct volume was analyzed by 2,3,5-triphenyltetrazolium chloride staining in rats and by magnetic resonance imaging in patients. Neurological function was assessed using modified Neurological Severity Score (mNSS) for rats and National Institutes of Health Stroke Scale (NIHSS) for patients.
RESULTS: Seven days post-MCAO, rats' FLT PET displayed higher SUVRs in the infarcted brain, declining gradually until Day 28. FLT-binding ratio (SUVR in the infarcted brain divided by that in contralateral side) correlated positively with stroke severity (p < 0.001), and to early mNSS decline in rats with mild to moderate stroke severity (p = 0.031). In 13 patients with cerebral infarct, FLT PET showed high SUVR in the infarcted regions. FLT-binding ratio correlated positively with infarct volume (p = 0.006). Age-adjusted initial NIHSS (p = 0.035) and early NIHSS decline (p = 0.076) showed significance or a trend toward positive correlation with the FLT-binding ratio.
INTERPRETATION: In vivo FLT PET detects poststroke cerebral cell proliferation, which is associated with stroke severity and/or outcomes in MCAO rats and patients with cerebral infarct.
PURPOSE:To obtain a cleaning agent compsn. with excellent foaming power and foam quality, reduced irritativeness to skins and hairs and furthermore improved cleaning properties by compounding a nonionic surfactant with a specified polyethyleneimine polymer. CONSTITUTION:A copolymer (A) with repeating units of formulas I and II (wherein R<1> is H, CH3 or C2H5; R<2> is a 4-15C alkyl, aryl or aralkyl) in a wt. ratio of formula I to formula II of 9/1 to 1/9 (polyethyleneimine polymer) and a nonionic surfactant (B) (e.g. polyoxyethylene alkyl ether) are compounded. Even though the nonionic surfactant has a feature of weak irritativeness to skins, there arises sometimes a problem on its inferior foaming power and foam quality to those of other surfactant. It is possible by the abovedescribed combination to obtain a cleaning agent compsn. with excellent foaming power and foam quality, reduced irritativeness to skins and hairs, and furthermore improve cleaning properties.
Patients should file away (with emery board) loose nail material and trim nails, as required, or as directed by the health care professional, every seven days after Ciclopirox topical solution, 8%, is removed with alcohol.

Ciclopirox topical solution, 8%, should be applied once daily (preferably at bedtime or eight hours before washing) to all affected nails with the applicator brush provided. The Ciclopirox topical solution, 8%, should be applied evenly over the entire nail plate.

If possible, Ciclopirox topical solution, 8%, should be applied to the nail bed, hyponychium, and the under surface of the nail plate when it is free of the nail bed (e.g., onycholysis).

The Ciclopirox topical solution, 8%, should not be removed on a daily basis. Daily applications should be made over the previous coat and removed with alcohol every seven days. This cycle should be repeated throughout the duration of therapy.
Indoxyl sulfate (IS) is one of the most potent uraemic toxins involved in the progression of chronic kidney disease (CKD) through the induction of inflammation and oxidative stress. This study assessed the potential benefits of reducing IS concentrations through dialysis treatment to improve renal function, inflammation, and oxidative stress. A prospective, observational cohort study of 50 patients with CKD undergoing dialysis treatment was conducted. IS levels, inflammatory markers (IL-6 and hs-CRP), and oxidative status (Cu/Zn-SOD) were measured using immunoenzymatic methods, and the albumin ratio (HNA/HMA) was assessed using high-performance liquid chromatography. Blood samples were collected at baseline and, at 8 weeks and 16 weeks after treatment. At baseline, patients with CKD had elevated levels of IS, renal function indicators, inflammatory markers (IL-6 and CRP), and oxidative markers (Cu/Zn-SOD and albumin ratio HNA/HMA). Dialysis treatment reduced IS levels, and a correlation among IS, renal function, and SOD levels (P < 0.0001) at 8 and 16 weeks was observed. The reduction in IS levels was associated with improved inflammatory marker levels (CRP and IL-6; P < 0.0001) and a significant decrease in the HNA/HMA ratio (P <0.0001) at 8 and 16 weeks. These associations strengthened over time. The results of this study suggest that IS levels may be a therapeutic target for improving outcomes in patients with CKD by improving renal function, inflammation, and oxidative stress. More research is needed to understand how IS contributes to CKD complications.
1,3 di-o-tolylguanidine (DTG) was examined as anti-stroke drug with a broad therapeutic window. DTG activates sigma 1 and 2 receptors. Administration of DTG at 24 hours post-stroke to rats reduces neurodegeneration by 85%; this is the only pharmacological agent that has been used successfully at this delayed timepoint. Treatment with DTG provides protection of neurons exposed to hypoxia and blocks activation of immune cells that are responsible for delayed neurodegeneration associated with stroke. Disclosed is an altered DTG structure, placing a bromide at the para position to increase tissue penetrance and efficacy. Results show that N,N′-di-p-bromophenyl guanidine protects cultured neurons under hypoxic conditions but is more potent than DTG. Moreover, N,N′-di-p-bromophenyl guanidine is as least as efficacious as DTG in treating rats 24 hours after experimental stroke.
For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
BACKGROUND: The rising prevalence of diabetes underscores the need for identifying effective prevention strategies. Recent research suggests environmental factors, particularly heavy metals like copper, significantly influence health outcomes, including diabetes, through mechanisms involving inflammation and oxidative stress. This study aims to explore how serum copper levels affect blood glucose, employing NHANES data from 2011 to 2016, to provide insights into environmental health's role in diabetes prevention and management.
METHODS: The study analyzed data from 2,318 NHANES participants across three cycles (2011-2016), focusing on those with available data on serum copper, inflammatory markers, and blood glucose levels. We utilized principal component analysis for selecting inflammatory markers, mediation analysis to examine direct and indirect effects, multiple linear regression for assessing relationships between markers and glucose levels, and weighted quantile sum regression for evaluating individual and collective marker effects, adjusting for demographic variables and serum copper.
RESULTS: Participants averaged 42.70 years of age, with a near-even split between genders. Average serum copper was 119.50 μg/dL, white blood cell count 6.82 × 109/L, and fasting blood glucose 107.10 mg/dL. Analyses identified significant mediation by inflammatory markers (especially white blood cells: 39.78%) in the copper-blood glucose relationship. Regression analyses highlighted a positive correlation between white blood cells (estimate: 1.077, 95% CI: 0.432 to 2.490, p = 0.013) and copper levels and a negative correlation for monocyte percentage (estimate: -1.573, 95% CI: 0.520 to -3.025, p = 0.003). Neutrophil percentage was notably influential in glucose levels. Sensitive analyses confirmed the study's findings.
CONCLUSION: Serum copper levels significantly impact blood glucose through inflammatory marker mediation, highlighting the importance of considering environmental factors in diabetes management and prevention. These findings advocate for public health interventions and policies targeting environmental monitoring and heavy metal exposure reduction, emphasizing the potential of environmental health measures in combating diabetes incidence.
Procedure to prepare the m-isonicotinilhirazona-benzaldehyde-sulphonate dihydrostreptomycin, solid and in solution at a certain concentration under sterile conditions, which in its industrial realization for a production in the order of 40-50 grams is characterized by, taking 350 cc of water solution of barite of title 0.0247 gr. Of ba (oh) 2 per c.c. Maintained in a steam bath at about 80-90º c, 31.56 gr. Is added in a fine stream with constant stirring. Of isonicotihilhidrazona acid of 3-benzaldehyde sulphonic interposed finely in 450 c.c. Of bidetilated water, obtaining a solution of ph = 7 to which is added 0.5 to 1 gr. Of activated carbon, whose solution is then filtered hot. (Machine-translation by Google Translate, not legally binding)
A method for treating a disease and drug units for use in performing such method. The method involves invading and flooding select cells of a living being with a drug or medical material to correct a genetic flaw, destroy or otherwise prevent the production or multiplication of a disease defining substance such as a virus in such cells or prevent the cells from uncontrollably growing or dividing. The method involves injecting or otherwise administering a dose of drug units to the body or bloodstream of a living being and targeting such drug units to the select cells to be treated and invaded with the drug of the units. In a preferred form, the drug is a derivative of vitamin A, such as 13-cis retinoic acid or other synthetic retinoid, which operates upon invading and flooding immature or precancerous white blood cells to restore the regulatory apparatus which they lack permitting them to mature normally and perform their normal functions such as their formation of platelets and preventing them from multiplying uncontrollably. The method involves forming such drug units of a small quantity of such drug, preferably encapsulated in a microcapsule or biodegradeable material and containing one or more targeting particles attached thereto for targeting or attaching the drug unit to the desired immature or diseased cell to be treated with the drug upon its attachment and release to the select cell to which the drug unit targets. In a particular form, select doses of such drug units are intermittently administered to the body or bloodstream by timed controlled administration of such select doses and/or by their timed release from a body implant employing biodegradation or other mechanism to effect such timed dose or drug unit release. In another form, the implant contains or is connected to a computer and includes means for detecting the presence and quantity or level of the cells requiring treatment, wherein the computer effects and controls the release of select quantities of such targeting drug units to the body or bloodstream in accordance with the information computed by the computer.
Central serous chorioretinopathy (CSCR) characterized by serous macular detachment is the fourth most common retinal disease after age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. In a population-based retrospective cohort and case control study in Olmsted county, Minnesota, USA, Kitzmann et al4 reported a mean age-adjusted incidence of 9.9 (95% confidence interval \[CI\] 7.4-12.4) per 100, 000 in men, and 1.7 (95% CI 0.7-2.7) in women. The mean age of onset of CSCR appears between 41 and 45 years5. The disease affects various racial groups5-8 and occasionally can be familial9. The pathogenesis remains poorly understood and currently the exudation is thought to result from hyper-permeable choroid secondary to venous stasis, ischemia, or inflammation2. Because of lack of proper animal models and lack of definite cure, clinical research has focused on risk factors such as stress, corticosteroid intake, and type A personality. Different hospital-based studies yielded different risk factors. Epidemiologic studies failed to ascertain many of these risk factors. Due to different methodology (retrospective vs. prospective case-control studies; selection of controls; questionnaire vs. interview by physician assistant vs. interview by physician) and focus on single risk factors in the literature, the investigators designed a study that targets a vast number of known or potential risk factors in various collaborative centers and compare it to results reported in the literature.
Second-line feeding strategies including hand expression and syringe feeding are used as an aid to breastfeeding, however little is known about their efficacy. This research explores the experiences of women who have used antenatal hand expression to identify how it affects maternal emotional health and breastfeeding continuation. UK women with recent experience of the practice were interviewed and the data analysed using thematic analysis. The results identified five themes in relation to these experiences including; The emotional distress of struggling with breastfeeding, Support as panacea but inconsistent, A crisis of confidence, Discord between knowledge, expectations and reality, and Syringe feeding as challenging but constructive. The study concludes that hand expression and syringe feeding supports women to establish breastfeeding, however, those struggling with breastfeeding need extra practical and emotional support to protect breastfeeding self-efficacy, emotional health and breastfeeding continuation. The findings highlight the importance of realistic, antenatal breastfeeding education to achieve this. Further research into second-line strategies and antenatal education programmes could contribute to the improvement of women's infant feeding experiences and improve UK breastfeeding rates.
Dietary pollution of Aflatoxin B1 (AFB1) poses a great threat to global food safety, which can result in serious hepatic injuries. Following the widespread use of plastic tableware, co-exposure to microplastics and AFB1 has dramatically increased. However, whether microplastics could exert synergistic effects with AFB1 and amplify its hepatotoxicity, and the underlying mechanisms are still unelucidated. Here, mice were orally exposed to 100 nm polystyrene nanoplastics (NPs) and AFB1 to investigate the influences of NPs on AFB1-induced hepatic injuries. We found that exposure to only NPs or AFB1 resulted in colonic inflammation and the impairment of the intestinal barrier, which was exacerbated by combined exposure to NPs and AFB1. Meanwhile, co-exposure to NPs exacerbated AFB1-induced dysbiosis of gut microbiota and remodeling of the fecal metabolome. Moreover, NPs and AFB1 co-exposure exhibited higher levels of systemic inflammatory factors compared to AFB1 exposure. Additionally, NPs co-exposure further exacerbated AFB1-induced hepatic fibrosis and inflammation, which could be associated with the overactivation of the TLR4/MyD88/NF-κB pathway. Notably, Spearman's correlation analysis revealed that the exacerbation of NPs co-exposure was closely associated with microbial dysbiosis. Furthermore, microbiota from NPs-exposed mice (NPsFMT) partly reproduced the exacerbation of NPs on AFB1-induced systemic and hepatic inflammation, but not fibrosis. In summary, our findings indicate that gut microbiota could be involved in the exacerbation of NPs on AFB1-induced hepatic injuries, highlighting the health risks of NPs.
FIELD: agriculture, in particular, methods for producing isomerized hop extract used in veterinary science, feeding and food industries. SUBSTANCE: method involves extraction of bitter, polyphenol and aromatic substances from hop, and, especially, from spent hop. The substances are extracted by hop boiling in aqueous solution with pH equals to 6-7 for not more than 60 min. Extraction of air fraction is carried out in rectified alcohol at temperature not higher 40 C. Mixing of fractions and the following their concentration under vacuum allows to bring content of dry substances up to 65%. EFFECT: higher efficiency. 4 cl, 1 dwg